ImpeDx Diagnostics has secured exclusive rights to develop and market a novel system for rapid antimicrobial susceptibility testing (AST), a multibillion dollar market.
Our mission is to reduce healthcare costs and the growing rate of antibiotic resistance while improving patient outcomes. Treating patients suffering from infections with targeted antibiotics and doses is the gold standard of care. Targeted treatment requires the results from a two-step process: 1) Identification & 2) AST. AST is the time consuming portion of the two-step process, often requiring days. Our technology compresses the typical AST “time-to-result” from days to under 4 hours.
ImpeDx is responding to an ever-growing need and significant medical problem, infections are the leading cause of death in hospitals today and antibiotic resistance is increasing at staggering rates globally. Not only will our rapid testing platform improve patient outcomes, but it will also have a major impact on healthcare savings.